In a follow-up to a previous study, surface contamination with the antineoplastic drug cyclophosphamide was compared in 30 US hospital pharmacies from 2004 to 2010 following preparation with standard drug preparation techniques or the PhaSeal closed system drug transfer device (CSTD).
Methods
Wipe samples were taken from biological safety cabinet (BSC) surfaces, BSC airfoils (the front leading edge of the BSC), floors in front of BSCs, and countertops in the pharmacy, and they were analyzed for contamination with cyclophosphamide. Contamination was reassessed after a minimum of 6 months following the implementation of the CSTD. Surface contamination (ng/cm2) was compared between the 2 techniques and between the previous and current test periods and evaluated with the Kruskal-Wallis test.
Results
With the use of CSTD compared to the standard preparation techniques, a significant reduction in levels of contamination with cyclophosphamide was observed (P < .0001). Median values for surface contamination with cyclophosphamide were reduced by 86% compared to 95% in the previous study.
Conclusions
The CSTD significantly reduced, but did not totally eliminate, surface contamination with cyclophosphamide. In addition to other protective measures, increased usage of CSTDs should be employed to help protect health care workers from exposure to hazardous drugs.
HemminkiKKyyronenPLindbohmM.Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985;39:141–147.
2.
SelevanSGLindbohmMHornungRW. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Eng J Med. 1985;313:1173–1178.
3.
ValanisBGHertzbergVShortridgeL.Antineoplastic drugs. Handle with care. AAOHN J. 1987; 35:487–492.
4.
McDonaldADMcDonaldJCArmstrongB. Congenital defects and work in pregnancy. Br J Ind Med. 1988;45:581–588.
5.
SkovTLyngeEMaarupB. Risks for physicians handling antineoplastic drugs [letter]. Lancet. 1990;2:1446.
6.
StuckerICaillardJFCollinR. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health. 1990;16:102–107.
7.
SkovTMaarupBOlsenJ. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992;49:855–861.
8.
LevinLIHollyEASewardJP. Bladder cancer in a 39-year old female pharmacist. J Natl Cancer Inst. 1993;85:1089–1091.
9.
McAbeeRRGallucciBJCheckowayH.Adverse reproductive outcomes and occupational exposures among nurses: an investigation of multiple hazardous exposures. AAOHN J. 1993;41:110–119.
10.
ValanisBGVollmerWMLabuhnKT. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993;50:455–462.
11.
ValanisBGVollmerWMLabuhnKT. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. 1993;16:288–295.
12.
HansenJOlsenJH. Cancer morbidity among Danish female pharmacy technicians. Scan J Work Environ Health. 1994;20:22–26.
13.
GunnarsdottirHKAspelundTKarlssonT. Occupational risk factors for breast cancer among nurses. Int J Occup Environ Health. 1997;3:254–258.
14.
ValanisBGVollmerWMLabuhnKT. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997;39:574–580.
15.
BouyerJSaurel-CubizollesMJGrenierC. Ectopic pregnancy and occupational exposure of hospital personnel. Scand J Work Environ Health. 1998;24:98–103.
16.
ValanisBVollmerWSteeleP.Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999;41:632–638.
17.
LorenteCCordierSBergeretA. Maternal occupational risk factors for oral clefts. Occupational exposure and congenital malformation working group. Scand J Work Environ Health. 2000;26:137–145.
18.
XieJWangJLiH. Epidemiological study of effect of occupational exposure to antineoplastic drugs on reproductive outcome in nurses. Cin J Ind Hyg Occup Dis. 2001;19: 87–90.
19.
FransmanWRoeleveldNPeelenS. Nurses with dermal exposure to antineoplastic drugs reproductive outcomes. Epidemiology. 2007;18:112–119.
20.
McDiarmidMAOliverMSRothTS. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 2010;52:1028–1034.
21.
LawsonCCRocheleauCMWhelanEA. Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol. 2012;206:327.e1-8.
22.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033–1049.
23.
AndersonRWPuckettWHDanaWJ. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982;39:1881–1887.
24.
SchierlRBohlandtANowakD.Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg. 2009;53:1–9.
25.
ConnorTHDeBordGPrettyJR. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med.2010; 52:1019–1027.
26.
SiderovJKirsaSMcLauchlanR.Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. J Oncol Pharm Practice.2010;16:19–25.
27.
YoshidaJKodaSNishidaS. Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. J Oncol Pharm Practice. 2010;17:29–38.
28.
SessinkPJMConnorTHJorgensonJA. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Practice. 2011;17:39–48.
29.
TurciRMinoiaCSottani. Occupational exposure to antineoplastic drugs in seven Italian hospitals: the effect of quality assurance and adherence to guidelines. J Oncol Pharm Practice.2011;17:320–332.
30.
NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004–165.
31.
American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm.2006;63:1172–1193.
32.
USP <797>: Guidebook to Pharmaceutical Compounding: Sterile Preparations.Rockville, MD: United States Pharmacopeia; 2008.
33.
SessinkPJMRolfM-AERydènNS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999;34:1311–1317.
34.
VandenbrouckeJRobaysH.How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice. 2001;6:146–152.
35.
ConnorTHAndersonRWSessinkPJ. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an IV admixture area. Am J Health Syst Pharm. 2002;59:68–72.
36.
NygrenOGustavssonBStrömL. Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit.2002;4:739–732.
37.
SpiveySConnorTH. Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system. Hosp Pharm. 2003;38:135–139.
38.
WickCSlawsonMHJorgensonJA. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003;60:2314–2320.
39.
HarrisonBRPetersBGBingMR. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm.2006;63:1736–1744.
40.
NygrenO.Wipe samples as a tool for monitoring aerosol deposition in workplaces. J Environ Monit.2006; 8;49–52.
41.
NymanHJorgensonJSlawsonMH. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm. 2007;42:219–225.
42.
NygrenOOlofssonEJohanssonL.Spill leakage using a drug preparing system based on double-filter technology. Ann Occup Hyg. 2008;52:95–98.
43.
YoshidaJTeiGMochizukiC. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg. 2009;53:153–160.
44.
ForgesFSimoensXChauvinF.Comparative parallel assessment of a transfer device in reducing 5-fluorouracil environmental contamination inside positive air pressure isolators. J Oncol Pharm Practice. 2010;17:61–67.
45.
ZockMDSoefjeSRickabaughK.Evaluation of surface contamination with cyclophosphamide following simulated hazardous drug preparation activities using two closed-system products. J Oncol Pharm Practice. 2010;17:49–54.
46.
Kandel-TschiedererKesslerMSchwietzerAMichelA.Reduction of workplace contamination with platinum-containing cytostatic drugs in a veterinary hospital by introduction of a closed system. Vet Record. 2010; June: 822–825.
47.
Le GarlantezecPRixxo-PadoinNAupeeO. Évaluation de la performance de dispositifs de transfert en système clos ay moyen d'une solution radioactive de [99mTc]. Ann Pharm Fr. 2011;69:182–191.
48.
SessinkPJMAnzionRBMvan den BroekPHH. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Week Sci.1992;14:16–22.
49.
SessinkPJMBoerKAScheefhalsAPH. Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992;64:105–112.
50.
SessinkPJMScholtesMMAnzionRBM. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr. 1993;616:333–337.
51.
McDevittJJLeesPSJMcDiarmidMA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993;35:57–60.
52.
EnsslinASPethranASchierlR. Urinary platinum in hospital personnel occupationally exposed to platinum containing antineoplastic drugs. Int Arch Occup Environ Health. 1994;65:339–342.
53.
SessinkPJMFriemèlNSSAnzionRBM. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health. 1994;65:401–403.
54.
SessinkPJMCernaMRössnerP. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res.1994;309:193–199.
55.
SessinkPJMvan de KerkhofMCAAnzionRBM. Environmental contamination and assessment of exposure to antineoplastic agents by detection of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route?Arch Environ Health. 1994;49:165–169.
56.
EnsslinASHuberRPethranA. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health. 1997;70:205–208.
57.
NygrenOLundgrenC.Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health. 1997;70:209–214.
58.
SessinkPJMWittenhorstBCJAnzionRBM. Exposure of pharmacy technicians to antineoplastic agents: re-evaluation after additional protective measures. Arch Environ Health. 1997;52:240–244.
59.
MinoiaCTurciRSottaniC. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom. 1998;12:1485–1493.
60.
SottaniCTurciRPerbelliniL. Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Comm Mass Spectrom. 1998;12:1063–1068.
61.
ConnorTHAndersonRWSessinkPJM. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm. 1999;56:1427–1432.
62.
RubinoFMFloridiaLPietropaoloAM. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: applications in occupational hygiene investigations in hospital environments. Med Lav. 1999;90:572–583.
63.
SessinkPJMBosRP. Drugs hazardous to healthcare workers. Drug Safety. 1999;20:347–359.
64.
KromhoutHHoekFUitterhoeveR. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg. 2000;44:551–560.
65.
TurciRMicoliGMinoiaC.Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatography: ultraviolet or tandem mass spectrometry detection. Rapid Comm Mass Spectrom. 2000;14:685–691.
66.
FavierBRullFMBertucatH. Surface and human contamination with 5-fluorouracil in six hospital pharmacies. J Pharmacie Clinique. 2001;20;157–162.
67.
MicoliGTurciRArpelliniM. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr. B. 2001;750:25–32.
68.
LeboucherGSerratriceFBertholleV. Evaluation of platinum contamination of a hazardous drug preparation area in a hospital pharmacy. Bull Cancer. 2002;89:949–955.
69.
TurciRSottaniCMinoiaC.Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Tox Lett.2002;134:57–64.
70.
SchmausGSchierlRFunckS.Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm. 2002;59:956–961.
71.
PethranASchierlRHauffK. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003;76:5–10.
72.
SchreiberCRadonKPethranA. Uptake of antineoplastic agents in pharmacy personnel. Part II: study of work-related risk factors. Int Arch Occup Environ Health. 2003;76:11–16.
73.
TurciRSottaniCSpagnoliG. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B. 2003;789:169–209.
74.
AcamporaACastigliaLMiragliaN. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg. 2005;49:611–618.
75.
Crauste-MancietSSessinkPJMFerrariS. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg. 2005;49:619–628.
76.
HedmerMGeorgiadiARämme BrembergE. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg. 2005;49:629–637.
77.
ZeedijkMGreijdanusBSteenstraFB. Monitoring exposure of cytotoxics on the hospital ward: measuring surface contamination of four different cytotoxic drugs from one wipe sample. Eur J Hosp Pharm. 2005;1:18–22.
78.
BussièresJFTheoretYProt-LabartheS. Program to monitor surface contamination by methotrexate in a hematology-oncology satellite pharmacy. Am J Health Syst Pharm.2007;64:531–535.
79.
GuerbetMGoulléJPLubranoJ.Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2007;33:623–629.
80.
CastigliaLMiragliaNPieriM. Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department. J Occup Health. 2008;50:48–56.
81.
HedmerMTinnerbergHAxmonA. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health. 2008;81:899–911.
82.
SchierlRBohlandtANowakD.Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg. 2009;53:1–9.
83.
TouzinKBussièresJF, Langlois É. Evaluation of surface contamination in a hospital hematology-oncology pharmacy. J Oncol Pharm Practice.2009;15:53–61.
84.
SugiuraSAsanoMKinoshitaK. Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J Oncol Pharm Practice.2010;17:14–19.
85.
ConnorTHSessinkPJMHarrisonBR. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm. 2005;62:475–484.
86.
SchierlRHerwigAPfallerA. Surface contamination of antineoplastic drug vials: comparison of unprotected and protected vials. Am J Health Syst Pharm. 2010;67:428–429.
87.
ConnorTHMcDiarmidMA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 2006;56:354–365.
88.
SessinkPJMKroeseEDvan KranenHJ. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1993;67:317–323.
89.
SessinkPJM. Environmental contamination with cytostatic drugs: past, present, future. Safety Considerations in Oncology Pharmacy. Special Edition. Fall 2011:3–5. www.ppme.eu.
